Q/C TECHNOLOGIES, INC. (QCLS): Nasdaq/NYSE listing notice — MyMD Pharmaceuticals receives Nasdaq deficiency notice for bid price below $1.00

Q/C TECHNOLOGIES, INC.

Received Nasdaq letter on Oct 11, 2023, for failing to maintain $1.00 closing bid price for 30 consecutive business days.
Has until April 8, 2024 (180-day compliance period) to regain compliance by achieving $1.00 closing bid for 10 consecutive days.
If not compliant by April 8, may receive additional 180-day cure period if meeting other listing standards.
No immediate delisting; stock continues trading on Nasdaq Capital Market.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.99

Q/C TECHNOLOGIES, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

October 11, 2023, MyMD Pharmaceuticals, Inc. (the “Company”) received a letter from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock for the 30 consecutive business days between August 29, 2023, to October 10, 2023, the Company did not meet the minimum bid price of $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2). The letter also indicated that the Company will be provided with a compliance period of 180 calendar days

View on SEC.gov

Browse all listing & compliance notices →

Q/C TECHNOLOGIES, INC. filing history →

Source: SEC EDGAR

accession 0001493152-23-037209

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.